Neurocrine Biosciences Inc (NBIX) stock
NBIXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 19/306% below fair value
$165.92+0.61 (+0.37%)
Close on Nov 17, 2026Market cap $16.87BP/E 24.3Yield –
Neurocrine Biosciences profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Neurocrine Biosciences's profit margin for the twelve months ending Jun 30, 2026 was 20.9%. For fiscal 2025 it was 16.7%, against 14.5% the year before. The highest annual figure on record is 48.5% in fiscal 2011.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 16.7% | +2.2 |
| FY2024 | Dec 31, 2024 | 14.5% | +1.3 |
| FY2023 | Dec 31, 2023 | 13.2% | +2.9 |
| FY2022 | Dec 31, 2022 | 10.4% | +2.5 |
| FY2021 | Dec 31, 2021 | 7.9% | −31.0 |
| FY2020 | Dec 31, 2020 | 38.9% | +34.2 |
| FY2019 | Dec 31, 2019 | 4.7% | +0.0 |
| FY2018 | Dec 31, 2018 | 4.7% | +92.9 |
| FY2017 | Dec 31, 2017 | -88.2% | +852.4 |
| FY2016 | Dec 31, 2016 | -940.6% | −490.8 |
| FY2015 | Dec 31, 2015 | -449.8% | +1129.1 |
| FY2013 | Dec 31, 2013 | -1579.0% | −1588.4 |
| FY2012 | Dec 31, 2012 | 9.5% | −39.1 |
| FY2011 | Dec 31, 2011 | 48.5% | +72.3 |
| FY2010 | Dec 31, 2010 | -23.8% | +1704.6 |
| FY2009 | Dec 31, 2009 | -1728.3% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 15.1% | −0.6 |
| Q1 FY2026 | Mar 31, 2026 | 24.3% | +22.9 |
| Q4 FY2025 | Dec 31, 2025 | 19.1% | +2.7 |
| Q3 FY2025 | Sep 30, 2025 | 26.4% | +5.5 |
| Q2 FY2025 | Jun 30, 2025 | 15.6% | +4.6 |
| Q1 FY2025 | Mar 31, 2025 | 1.4% | −7.0 |
| Q4 FY2024 | Dec 31, 2024 | 16.4% | −12.2 |
| Q3 FY2024 | Sep 30, 2024 | 20.9% | +4.2 |
| Q2 FY2024 | Jun 30, 2024 | 11.0% | −10.1 |
| Q1 FY2024 | Mar 31, 2024 | 8.4% | +26.6 |
| Q4 FY2023 | Dec 31, 2023 | 28.7% | +7.1 |
| Q3 FY2023 | Sep 30, 2023 | 16.7% | −1.0 |
| Q2 FY2023 | Jun 30, 2023 | 21.1% | +25.6 |
| Q1 FY2023 | Mar 31, 2023 | -18.2% | −22.7 |
| Q4 FY2022 | Dec 31, 2022 | 21.6% | +23.9 |
| Q3 FY2022 | Sep 30, 2022 | 17.7% | +10.1 |
| Q2 FY2022 | Jun 30, 2022 | -4.5% | −19.1 |
| Q1 FY2022 | Mar 31, 2022 | 4.5% | −9.1 |
| Q4 FY2021 | Dec 31, 2021 | -2.3% | −142.7 |
| Q3 FY2021 | Sep 30, 2021 | 7.6% | +29.9 |
| Q2 FY2021 | Jun 30, 2021 | 14.6% | −11.7 |
| Q1 FY2021 | Mar 31, 2021 | 13.6% | −2.2 |
| Q4 FY2020 | Dec 31, 2020 | 140.3% | +126.4 |
| Q3 FY2020 | Sep 30, 2020 | -22.3% | −46.5 |
| Q2 FY2020 | Jun 30, 2020 | 26.3% | −1.6 |
| Q1 FY2020 | Mar 31, 2020 | 15.8% | +89.5 |
| Q4 FY2019 | Dec 31, 2019 | 13.9% | +0.2 |
| Q3 FY2019 | Sep 30, 2019 | 24.2% | −9.2 |
| Q2 FY2019 | Jun 30, 2019 | 28.0% | +34.1 |
| Q1 FY2019 | Mar 31, 2019 | -73.8% | −14.9 |
| Q4 FY2018 | Dec 31, 2018 | 13.7% | +6.5 |
| Q3 FY2018 | Sep 30, 2018 | 33.5% | +51.8 |
| Q2 FY2018 | Jun 30, 2018 | -6.1% | +940.8 |
| Q1 FY2018 | Mar 31, 2018 | -58.8% | – |
| Q4 FY2017 | Dec 31, 2017 | 7.3% | – |
| Q3 FY2017 | Sep 30, 2017 | -18.3% | – |
| Q2 FY2017 | Jun 30, 2017 | -946.9% | – |
See a number that looks wrong?